Nexalin Technology Advances Pivotal Clinical Trial for HALO™ Clarity Device
Nexalin Technology (NXL) has advanced its pivotal clinical trial for the HALO™ Clarity device, targeting enrollment in Q2 2026. The 160-participant, triple-blinded, sham-controlled study aims to support a De Novo FDA submission for the treatment of moderate-to-severe insomnia. The trial is being conducted in collaboration with Lindus Health.
Topics: clinical trial FDA submission insomnia treatment medical device